Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis
- PMID: 11304501
- DOI: 10.1161/01.hyp.37.4.1047
Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis
Abstract
There is increasing evidence that direct pathobiological events in the vessel wall play an important role in vascular disease. An important mechanism involves the perturbation of the homeostatic balance between NO and reactive oxygen species. Increased reactive oxygen species can inactivate NO and produce peroxynitrite. Angiotensin II is a potent mediator of oxidative stress and stimulates the release of cytokines and the expression of leukocyte adhesion molecules that mediate vessel wall inflammation. Inflammatory cells release enzymes (including ACE) that generate angiotensin II. Thus, a local positive-feedback mechanism could be established in the vessel wall for oxidative stress, inflammation, and endothelial dysfunction. Angiotensin II also acts as a direct growth factor for vascular smooth muscle cells and can stimulate the local production of metalloproteinases and plasminogen activator inhibitor. Taken together, angiotensin II can promote vasoconstriction, inflammation, thrombosis, and vascular remodeling. In this article, we propose a model that unifies the interrelationship among cardiovascular risk factors, angiotensin II, and the pathobiological mechanisms contributing to cardiovascular disease. This model may also explain the beneficial effects of ACE inhibitors on cardiovascular events beyond blood pressure reduction.
Similar articles
-
Interactions among ACE, kinins and NO.Cardiovasc Res. 1999 Aug 15;43(3):549-61. doi: 10.1016/s0008-6363(99)00091-7. Cardiovasc Res. 1999. PMID: 10690327 Review. No abstract available.
-
ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury.Antioxid Redox Signal. 2017 Apr 20;26(12):645-659. doi: 10.1089/ars.2016.6950. Epub 2017 Jan 12. Antioxid Redox Signal. 2017. PMID: 27889958 Review.
-
The renin-angiotensin-aldosterone system: a specific target for hypertension management.Am J Hypertens. 1999 Dec;12(12 Pt 3):205S-213S. doi: 10.1016/s0895-7061(99)00103-x. Am J Hypertens. 1999. PMID: 10619573 Review.
-
Counter-regulatory effects played by the ACE - Ang II - AT1 and ACE2 - Ang-(1-7) - Mas axes on the reactive oxygen species-mediated control of vascular function: perspectives to pharmacological approaches in controlling vascular complications.Vasa. 2014 Nov;43(6):404-14. doi: 10.1024/0301-1526/a000387. Vasa. 2014. PMID: 25339158 Review.
-
Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology.Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1302-14. doi: 10.1089/ars.2005.7.1302. Antioxid Redox Signal. 2005. PMID: 16115036 Review.
Cited by
-
Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.Circ Res. 2012 May 11;110(10):1322-35. doi: 10.1161/CIRCRESAHA.112.268029. Epub 2012 Apr 3. Circ Res. 2012. PMID: 22474255 Free PMC article.
-
The effects of angiotensin-converting enzyme-inhibitory peptide LAP on the left common carotid artery remodeling in spontaneously hypertensive rats.Ir J Med Sci. 2013 Dec;182(4):711-8. doi: 10.1007/s11845-013-0963-5. Epub 2013 May 10. Ir J Med Sci. 2013. PMID: 23661144
-
Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.Am J Physiol Regul Integr Comp Physiol. 2012 Mar 1;302(5):R494-509. doi: 10.1152/ajpregu.00487.2011. Epub 2011 Dec 14. Am J Physiol Regul Integr Comp Physiol. 2012. PMID: 22170616 Free PMC article. Review.
-
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.Br J Clin Pharmacol. 2013 Feb;75(2):415-22. doi: 10.1111/j.1365-2125.2012.04358.x. Br J Clin Pharmacol. 2013. PMID: 22703472 Free PMC article. Clinical Trial.
-
Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?Curr Hypertens Rep. 2002 Aug;4(4):290-7. doi: 10.1007/s11906-996-0007-x. Curr Hypertens Rep. 2002. PMID: 12117456 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous